Please select the eligibility criteria that correspond to the clinical trial below.
Title: Comparative Effectiveness of Pregnancy Failure Management Regimens
Brief Summary: The purpose of the study is to compare the effectiveness of combination treatment (mifepristone premedication plus single-dose misoprostol) to single-dose misoprostol (standard of care) for the management of early pregnancy failure.


Options:
A: Inclusion Criteria:

* bleeding and contractions during pregnancy

Exclusion Criteria:

* women with known allergy to misoprostol,
* a uterine size more than 12 weeks of gestation,
* suspected ectopic pregnancy,
* unstable hemodynamic status and chock,
* signs of pelvic infection and/or sepsis.
B: Inclusion Criteria:

* between 5 and 12 completed weeks gestation
* 18 years or older
* hemodynamically stable
* confirmed diagnosis of intrauterine embryonic/fetal demise or anembryonic gestation (ultrasound examination demonstrates a fetal pole without cardiac activity measuring between 5.3 and 40 mm or an abnormal growth pattern diagnostic of early pregnancy failure)
* willing and able to give informed consent

Exclusion Criteria:

* diagnosis of incomplete or inevitable abortion (absent gestational sac and/or active bleeding, open cervical os)
* contraindication to mifepristone (chronic corticosteroid administration, adrenal disease)
* contraindication to misoprostol (glaucoma, mitral stenosis, sickle cell anemia, or known allergy to prostaglandin)
* cardiovascular disease (angina, valvular disease, arrhythmia, or cardiac failure)
* most recent hemoglobin \<9.5 g/dL
* diagnosis of porphyria
* known clotting defect or receiving anticoagulants
* pregnancy with an intrauterine device (IUD) in place
* breastfeeding during the first 7 days of study participation
* unwilling to comply with the study protocol and visit schedule
* any evidence of viable pregnancy
* possibility of ectopic pregnancy
* known or suspected pelvic infection
* concurrent participation in any other interventional trial
C: Inclusion Criteria:

* Before randomization: Gestational age not more than 63 days as estimated by last menstrual period (LMP).
* After randomization: Gestational age not more than 63 days as estimated by abdominal and bimanual pelvic examination.
* Above national age of consent
* Willing to return to the clinic for misoprostol on Day 3 and for a follow-up visit on Day 10 to 14.
* Residence within the geographical area specified for each clinic and no more than one hour from emergency referral services.
* Willing to provide written informed consent to participate in the study and to be randomly assigned to a provider team.
* Able to understand the nature of the study, advice and instructions given by health providers.

Exclusion Criteria:

* Previous allergic reaction to one of the drugs in the medical abortion regimen
* Known or suspected ectopic pregnancy or undiagnosed adnexal mass
* Inherited porphyria (rare genetic blood diseases)
* Chronic adrenal failure
* Long term corticosteroid therapy
* Haemorrhagic disorder or anticoagulant therapy (blood thinner medications)
* IUD in utero that can not be removed before taking mifepristone
* Previous enrolment in the study (i.e. no repeat abortions; only one abortion per woman in the study)
* Unwilling or unable to return to clinic for follow-up visit.
D: Inclusion Criteria:

* healthy women aged 18-45 with no contraindication to medical abortion

Exclusion Criteria:

* any medical condition which contraindicates medical abortion

Answer: B